Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Je tříměsíční léčba cyklofosfamidem dostatečná z hlediska snížení rizika relapsů ANCA-pozitivní renální vaskulitidy?

David Jayne et al.

Language Czech Country Czech Republic

Document type Multicenter Study

Digital library NLK
Issue
Volume
Source

BACKGROUND: The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. METHODS: We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. RESULTS: Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03). CONCLUSIONS: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.

000      
00000naa 2200000 a 4500
001      
bmc10019817
003      
CZ-PrNML
005      
20180625073928.0
008      
100908s2003 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Jayne, David $7 xx0225517
245    10
$a Je tříměsíční léčba cyklofosfamidem dostatečná z hlediska snížení rizika relapsů ANCA-pozitivní renální vaskulitidy? / $c David Jayne et al.
314    __
$a Department of Medicine, Addenbrooke's Hospital, Cambridge
520    9_
$a BACKGROUND: The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. METHODS: We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. RESULTS: Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03). CONCLUSIONS: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a financování organizované $7 D005381
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protilátky proti cytoplazmě neutrofilů $x krev $7 D019268
650    _2
$a azathioprin $x škodlivé účinky $x terapeutické užití $7 D001379
650    _2
$a cyklofosfamid $x škodlivé účinky $x terapeutické užití $7 D003520
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glukokortikoidy $x terapeutické užití $7 D005938
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neutropenie $x chemicky indukované $7 D009503
650    _2
$a prednisolon $x terapeutické užití $7 D011239
650    _2
$a recidiva $7 D012008
650    _2
$a indukce remise $7 D012074
650    _2
$a vaskulitida $x farmakoterapie $x imunologie $x mortalita $7 D014657
655    _2
$a multicentrická studie $7 D016448
773    0_
$w MED00012709 $t Postgraduální nefrologie $g Roč. 1, č. 3 (2003), s. 5-6 $x 1214-178X
910    __
$a ABA008 $b B 2318 $c 893 $y 7 $z 0
990    __
$a 20100830113932 $b ABA008
991    __
$a 20180625074158 $b ABA008
999    __
$a ok $b bmc $g 768841 $s 632773
BAS    __
$a 3
BMC    __
$a 2003 $b 1 $c 3 $d 5-6 $m Postgraduální nefrologie $x MED00012709
LZP    __
$a 2010-24/mkme

Find record